The increasing interest in effective weight management has led to considerable exploration into cutting-edge treatments. Currently, Retatrutide, a combined -action hormone and glucagon-like peptide-1 (GLP-1) receptor agonist , has demonstrated promising results in patient trials, indicating potential for substantial weight reduction . As a result ,